Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MALIGNANT PLEURAL MESOTHELIOMA
Autore:
BOUTIN C; SCHLESSER M; FRENAY C; ASTOUL P;
Indirizzi:
HOP CONCEPTION,DEPT PULM DIS,147 BD BAILLE F-13385 MARSEILLE 5 FRANCE UNIV MEDITERRANEAN,UPRES 2050 MARSEILLE FRANCE
Titolo Testata:
The European respiratory journal
fascicolo: 4, volume: 12, anno: 1998,
pagine: 972 - 981
SICI:
0903-1936(1998)12:4<972:MPM>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
188 CONSECUTIVE PATIENTS; PHASE-II TRIAL; INTERFERON-GAMMA; ASBESTOS FIBERS; CELL-LINES; RECOMBINANT INTERLEUKIN-2; BRONCHOALVEOLAR LAVAGE; MULTIMODALITY THERAPY; MONOCLONAL-ANTIBODY; RANDOMIZED TRIAL;
Keywords:
ASBESTOS; CYTOKINES; MALIGNANT MESOTHELIOMA; PLEURA; THORACOSCOPY;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
113
Recensione:
Indirizzi per estratti:
Citazione:
C. Boutin et al., "MALIGNANT PLEURAL MESOTHELIOMA", The European respiratory journal, 12(4), 1998, pp. 972-981

Abstract

The incidence of malignant pleural mesothelioma (MPM) has risen for some decades and is expected to peak between 2010 and 2020, Up to now no single treatment has been proven to be effective and death usually occurs within about 12- 17 months after diagnosis. Perhaps because of this poor prognosis, early screening has incited little interest However, certain forms may have a better prognosis when diagnosed early and treated by multimodal therapy or intrapleural immunotherapy, Diagnosisdepends foremost on histological analysis of samples obtained by thoracoscopy This procedure allows the best staging of the pleural cavity with an attempt to detect visceral pleural involvement, which is one of the most important prognostic France factors, Although radiotherapy seems necessary and is efficient in preventing the malignant seeding after diagnostic procedures in patients,there has been no randomized phase III study showing the superiority of any treatment compared with another. However, for the early-stage disease (stage I) a logical therapeutic approach seems to be neoadjuvant intrapleural treatment using cytokines, For more advanced disease (stages II and III) resectability should be discussed with the thoracic surgeons and a multimodal treatment combining surgery, radiotherapy and chemotherapy should be proposed for a randomized controlled study. Palliative treatment is indicatedfor stage IV, In any case, each patient should be enrolled in a clinical trial. (C) ERS Journals Ltd 1998.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 00:51:46